Drugs / ALTA2618
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06533059 | Aug 2024 → Dec 2026 expected | breast cancer, endometrial cancer, metastatic malignant neoplasm | Alterome Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTA2618 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533059 ↗ |
| Action | Inhibit | “mutant-selective and orally bioavailable AKT1 E17K inhibitor” NCT06533059 ↗ |
| Route | Oral | “Oral ALTA2618 tablets will be administered at protocol-defined dose” NCT06533059 ↗ |
| Target | AKT1 | “mutant-selective and orally bioavailable AKT1 E17K inhibitor” NCT06533059 ↗ |